Sportoletti et al. demonstrated that NPM1 acts indeed as a haploinsufficient tumor suppressor gene in vivo [12], while some findings suggested that NPM1 mutation in AML is likely a gain-of-function one rather than simple haploinsufficiency [13]. The gene discussed is NPM1; the disease is acute myeloid leukemia.